Literature DB >> 973970

Rectal administration of feprazone in healthy volunteers.

P Ferrari, C Montanari, P Sala, A Vidi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 973970      PMCID： PMC1428872          DOI： 10.1111/j.1365-2125.1976.tb00616.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  6 in total

1.  Clinical and laboratory evaluation of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370) in rheumatoid arthritis and ankylosing spondylitis.

Authors:  G C Lignière; B Colombo; M Carrabba; P Ferrari; E Robotti
Journal:  Arzneimittelforschung       Date:  1972-01

2.  The use of balanced incomplete block designs in comparative bioavailability trails.

Authors:  W J Westlake
Journal:  Biometrics       Date:  1974-06       Impact factor: 2.571

3.  Physico-chemical and analytical studies on 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370).

Authors:  R Perego; A Gallazzi; P C Vanoni; I Lucarella
Journal:  Arzneimittelforschung       Date:  1972-01

4.  A double-blind cross-over trail of Prenazone and aspirin in the management of rheumatoid arthritis.

Authors:  R Billings; H C Burry; R Grahame; D J Berry; B Donovan
Journal:  Rheumatol Rehabil       Date:  1975-05

5.  Feprazone, a new anti-inflammatory agent. Studies of potency and gastrointestinal tolerance.

Authors:  M R Fletcher; W Loebl; J T Scott
Journal:  Ann Rheum Dis       Date:  1975-04       Impact factor: 19.103

6.  Feprazone compared with indomethacin in the management of rheumatoid arthritis.

Authors:  R Sturrock; A Isaacs; F D Hart
Journal:  Practitioner       Date:  1975-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.